Iradimed Corp Eyes 2026 Surge After Strong Quarter

Iradimed Corp ((IRMD)) has held its Q4 earnings call. Read on for the main highlights of the call.

Iradimed Corp’s latest earnings call carried a notably upbeat tone, with management highlighting another quarter of record revenue, expanding earnings per share, and robust cash generation. Executives balanced this optimism with clear acknowledgment of execution risks tied to the rollout of the new 3870 pump and the company’s heavy reliance on the U.S. market for growth.

Record Revenues and Sustained Growth Momentum

Iradimed posted Q4 2025 revenue of $22.7 million, up 17% year over year, bringing fiscal 2025 sales to $83.8 million, a 14% increase. This marks the company’s 18th consecutive quarter of record revenue, underscoring consistent demand for its MRI‑compatible devices despite a cautious hospital capital spending backdrop.

Profitability Trends Move Higher

Profitability improved alongside revenue, with Q4 GAAP diluted EPS rising 25% to $0.50 and non‑GAAP EPS up 23% to $0.54. For the full year, GAAP diluted EPS climbed 17% to $1.75 and non‑GAAP EPS advanced 16% to $1.93, reflecting operating leverage even as the company invests for its next growth leg.

High and Stable Gross Margins

Gross margins remained a standout feature, at roughly 75% in Q4 and about 77% for the full year, essentially flat with the prior year. Management presented this as evidence of a durable high‑margin business model, though they cautioned about some temporary pressure during the early stages of the 3870 production ramp.

Product Mix Shows Broad‑Based Strength

MRI‑compatible IV infusion pump systems delivered $9.1 million of Q4 revenue, up 20% year over year, confirming their status as a core growth driver. Patient vital signs monitoring systems reached $7.1 million, up 7.5%, while disposable revenue rose 18% to $4.3 million and ferromagnetic detection products also posted gains, signaling healthy demand across the portfolio.

Cash Generation and Operational Income Remain Solid

The company ended the year with $51.2 million in cash and equivalents, giving it ample flexibility to support the 3870 launch and ongoing R&D. Q4 operating income was $7.1 million and full‑year operating income $26.1 million, while cash flow from operations reached $5.9 million in Q4 and $24.9 million for the year, complemented by non‑GAAP free cash flow of $5.5 million in Q4 and $16.5 million for the year.

New 3870 Pump Launch and ASP Upside

Iradimed has begun its transition to the new 3870 MR IV pump, with 23 units shipped in December as part of an early rollout. Management expects the 3870 to command 10%–14% higher average selling prices than its predecessor and to support higher utilization and greenfield penetration, positioning the pump as a key lever for revenue and margin expansion over time.

Large Replacement Market and 2026 Revenue Ambitions

The U.S. installed base includes about 6,400 pump channels from the older 3860/3861 platform that are at least five years old and ripe for replacement. Iradimed currently sells roughly 1,100 channels domestically per year, but aims to add around 1,000 replacement channels annually starting in Q2 2026, targeting sales of more than 2,000 3870 channels a year and an estimated $50 million pump run rate that supports a $100 million‑plus company revenue run rate in 2026.

Positive Early Feedback and Controlled Commercial Rollout

Early clinical and user feedback on the 3870 was described as very positive, with clinicians reportedly excited about the new system’s capabilities. The company is following a controlled launch strategy, using a limited pre‑launch deployment to refine the product and planning a broader commercial release in April with an initial shipment target of about 100–130 channels.

R&D Roadmap Extends Growth Beyond the Pump Cycle

Beyond the 3870 pump, management highlighted ongoing R&D investment in a next‑generation MRI monitor. Development work is already underway, with a market update targeted around 2028, signaling that Iradimed aims to sustain its technology edge and diversify future sources of growth beyond the current pump replacement wave.

Inventory and Transition Challenges in the Pump Swap

Management stressed that carefully managing inventory during the shift from the 3860 to the 3870 will be critical, noting that Q4 inventory rose as components for the new system were built up. The transition is expected to be particularly challenging around Q2 2026, when the company must balance legacy product support with scaling production and deliveries of the new platform.

Margin Pressure During Early 3870 Ramp

The CFO cautioned that gross margins are likely to be merely in line in the first half of 2026 as production volumes for the 3870 are still subscale. Management expects margins to trend higher in the second half once manufacturing efficiencies kick in, but investors should be prepared for some near‑term compression as the transition progresses.

Geographic Concentration in the U.S. Market

Domestic sales accounted for 81% of Q4 revenue and 84% of full‑year revenue, underscoring Iradimed’s heavy dependence on U.S. hospital demand. While this concentration has helped the company execute tightly and grow quickly, it also leaves results vulnerable if U.S. capital spending slows or competitive dynamics intensify before international markets scale.

Rising Operating Expenses to Support Growth

Operating expenses were $9.9 million in Q4 and $38.2 million for the year, reflecting higher general and administrative spending to support the expanding business and new product launch. Management believes this elevated cost base is necessary for growth, but it could weigh on margins if the 3870 revenue ramp is delayed or falls short of expectations.

International Launch Delays Temper Near‑Term Upside

International growth from the 3870 will be muted in the near term because key regulatory approvals are still pending. The company does not expect to secure major clearances in Europe and Japan until late 2026 and mid‑2027 respectively, pushing out the timing of meaningful overseas contributions and keeping the growth story largely U.S.‑centric for now.

Execution Risk from Conservative Initial Shipments

Iradimed’s initial broad shipment plan for the 3870 is modest, with about 100–130 channels expected in April and bookings projected to build in the second half of 2026. Achieving the company’s ambitious 2026 run‑rate targets will depend on smooth execution, timely hospital purchasing approvals, and efficient scaling of manufacturing and field support.

Forward‑Looking Risk Factors Remain in Focus

Management reiterated that future results depend heavily on the pace of pump replacement cycles, customer approval processes, and the company’s ability to scale production and logistics. They emphasized that these operational and market risks could materially impact the trajectory toward their stated revenue goals, urging investors to remain mindful of the uncertainties embedded in the transition.

Guidance and Outlook Centered on 3870‑Driven Acceleration

Looking ahead, Iradimed’s guidance is anchored on the 3870 pump driving meaningful upside through higher deal ASPs and a doubling of annual domestic channel sales to more than 2,000 units by 2026. Management expects this to yield an approximate $50 million pump revenue run rate and, together with disposables, maintenance, international sales, and MRI monitoring, a company‑wide revenue run rate above $100 million in 2026, with a controlled launch in 2025 designed to bridge the ramp.

Iradimed’s earnings call painted the picture of a company in strong financial health, leveraging record revenues and high margins to fund a pivotal product transition. The opportunity around the 3870 pump is significant and could lift the company into a higher revenue tier by 2026, but investors will be watching closely to see if management can navigate inventory, margin, and regulatory challenges without derailing the growth story.